Marshall Wace, LLP Dyne Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 3,013,377 shares of DYN stock, worth $56.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,013,377
Previous 447,807
572.92%
Holding current value
$56.8 Million
Previous $4.26 Million
794.18%
% of portfolio
0.04%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding DYN
# of Institutions
227Shares Held
144MCall Options Held
170KPut Options Held
229K-
Janus Henderson Group PLC London, X014.7MShares$278 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.76MShares$184 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$172 Million26.07% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$139 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$103 Million13.81% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $975M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...